



# ANTIMICROBIAL CHEMOTHERAPY CONFERENCE 2019

AN ABC FOR EVERYONE  
INVOLVED IN DEVELOPING  
NEW ANTIMICROBIALS



In collaboration with Global  
Antibiotic Research & Development  
Partnership (GARDP)

**London, 2019**

**15 January**

**Seligman Theatre, Royal College of Physicians**

# PROGRAMME - 15 JANUARY

0830 **Registration and refreshments**

---

0930 **Opening remarks**

*Professor Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP)*

---

## SESSION ONE: Antimicrobial drug discovery - an essential overview

*Chair: Professor William Hope, Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool*

0935 **What are the essential components of a drug discovery pipeline?**

*Dr David Shlaes, Former Professor of Medicine, Case Western Reserve University, Ohio, USA*

1000 **Overview of new antibiotics in development**

*Professor David Livermore, Professor of Medical Microbiology, University of East Anglia*

1025 **Overview of new antifungals in development**

*Professor David Denning, Professor of Infectious Diseases in Global Health, University of Manchester*

---

1050 **Refreshments and posters**

---

## SESSION TWO: Things we forget that come back to bite us!

*Chair: Professor David Livermore, Professor of Medical Microbiology, University of East Anglia*

1120 **Things clinicians don't often consider (CMC, GLP toxicology, Phase I studies)**

*Dr Richard FitzGerald - CRF Director, NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Consultant Physician, Clinical Pharmacology & Therapeutics / General Medicine, Honorary Senior Lecturer, Molecular & Clinical Pharmacology, University of Liverpool*

1145 **PK-PD programs for drug development**

*Professor George Drusano, University of Florida and an Institute Director (Institute for Therapeutic Innovation)*

1210 **Invited paper selected from abstracts**

---

1230 **Lunch, posters and interactive sessions**

- **Interaction two: Hollow fibre corner**

*Mr Adam Johnson, Senior Research Assistant, Molecular and Clinical Pharmacology, University of Liverpool*

### **SESSION THREE: Tackling Beta-lactamase mediated resistance**

*Chair: Professor Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP)*

1330 **Beta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of beta-lactamase inhibitor combinations**

*Dr Shampa Das, Senior Lecturer, Molecular and Clinical Pharmacology, University of Liverpool*

1355 **Metallobetalactamases and development of new compounds**

*Mr Martin Everett, Chief Scientific Officer, Antabio*

1420 **Invited paper selected from abstracts**

---

### **SESSION FOUR: The Way Forward: Clinical Trial Design and New Drug Development**

*Chair: Professor William Hope, Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool*

1440 **Stimulating Antibiotic R&D through links to sustainable use and novel economic incentives**

*Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents*

1505 **Clinical Trial Design for new antimicrobials: adults**

*Mr Aaron Dane, Director, DaneStat Consulting Limited*

1530 **Innovative clinical trial design for unmet clinical needs: neonatal sepsis**

*Speaker tbc*

1555 **Developing a new drug for STIs**

*GARDP speaker tbc*

---

1620 **Closing remarks**

*Professor William Hope, Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool*